株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場競争環境:非アルコール性脂肪肝炎 (NASH)

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

発行 GlobalData 商品コード 758924
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
市場競争環境:非アルコール性脂肪肝炎 (NASH) Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
出版日: 2018年11月30日 ページ情報: 英文 52 Pages
概要

当レポートでは、非アルコール性脂肪肝炎 (NASH) の治療薬の開発状況と市場競争の見通しについて分析し、主要企業の最新情勢や将来展望、今後の事業展開の方向性 (市場参入など)、主なパイプライン製品の概略と治験の見通し、現在/将来の製品ポジショニングなどについて調査しております。

イントロダクション

エグゼクティブ・サマリー

  • 昨今の主な出来事と市場情勢

市場情勢

  • 市場参入/製品上市の見通し
  • 主要企業の市場参入戦略
  • ライフサイクル管理の動向
  • 主要企業の「進行方向」

パイプライン環境

  • パイプライン製品の概略

付録

目次
Product Code: GDHC062SP

"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time

The report comprises three sections -

Executive Summary

  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.

Landscape Updates

  • 'Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline therapies.

Pipeline Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2020.

Appendix

  • Current early stage RA pipeline & candidate 'Watch List'.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Table of Contents

Introduction to Sociable Pharma's 'Competitor Landscape'

Executive Summary

  • Key Events & Landscape Updates

Landscape Updates

  • Order of Entry
  • Key Competitor Market Entry Strategies
  • Lifecycle Development
  • Key Competitor 'Direction of Travel'

Pipeline Landscape

  • Pipeline Summary

Appendix

Back to Top